

The Role of Ultrasound in Thyroid Assessment

Yusuf Bakkar ¹
Rana Bakkar ²

(1) Specialist in Diagnostic Radiology, Gulf laboratory and x-ray, Qatar

(2) Consultant Radiologist in PHCC, Qatar, Al Thumama HC Primary Health Care

Corresponding author:

Yusuf Bakkar

Specialist in Diagnostic Radiology, Gulf laboratory and x-ray,
Qatar

Email: yousefd38@gmail.com

Received: February 2023 Accepted: March 2023; Published: April 1, 2023.

Citation: Yusuf Bakkar, Rana Bakkar. The Role of Ultrasound in Thyroid Assessment World Family Medicine. March 2023; 21(3): 97-106 DOI: 10.5742/MEWFM.2023.95256079

Abstract

The recent prevalence of ultrasonography (US) has facilitated the early detection and qualitative evaluation of thyroid nodules. Furthermore, novel technical developments are extending the application range of US for other thyroid diseases.

The use of US to differentiate between thyroid carcinoma and benign nodule, between a metastatic lymph node and a reactive node, between thyroid lymphoma and chronic thyroiditis, and between destruction-induced thyrotoxicosis and Graves' disease is introduced.

Classification systems for thyroid nodule have shown high diagnostic accuracy for thyroid carcinomas except follicular carcinoma. US diagnosis of lymph node metastasis showed high specificity but low sensitivity. Patients who were suspected of thyroid lymphoma based on US findings should undergo incisional biopsy or thyroidectomy for diagnosis of the histologic type if fine needle aspiration biopsy findings suggest lymphoma. Patients should be carefully followed even if they were diagnosed as negative based on cytologic findings. Measurement of thyroid blood flow is helpful for diagnosing destruction-induced thyrotoxicosis, such as painless thyroiditis, by distinguishing the lesion from Graves' disease.

Ultrasonography is useful for diagnosing various thyroid diseases, including thyroid carcinoma. The remaining issue to be resolved is the diagnosis of follicular carcinoma. Trials using novel techniques to differentiate these lesions are expected.

Key words: ultrasound, thyroid assessment

Introduction

The thyroid gland can be evaluated using several imaging modalities such as radionuclide imaging, ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI). Although each study has advantages and drawbacks, US is the most useful tool for detecting and diagnosing thyroid diseases, especially thyroid nodules. This is because US not only detects the nodules but also allows qualitative evaluation of these lesions. The recent prevalence and technical developments of US have resulted in its increased use for mass screening of the thyroid and carotid artery and have facilitated the incidental detection of nonpalpable thyroid nodules measuring > 3 mm. Using a combination of US and US-guided fine needle aspiration biopsy (FNAB), these nodules can be differentiated as benign or malignant [1].

Apart from the diagnosis of thyroid nodules, US is useful for the qualitative diagnosis of regional lymph nodes, which is important for determining the extension of lymph node dissection and evaluating the biologic behavior, including prognosis, of thyroid carcinoma patients. Furthermore, US can facilitate the differential diagnosis between thyroid lymphoma and chronic thyroiditis and between destruction-induced thyrotoxicosis, such as painless thyroiditis, and Graves' thyrotoxicosis. In this review, we introduce the utility of thyroid US based on data from our institution together with data from other institutions.

Since the late 1990s, several studies have been conducted to analyze the relation between specific sonographic features of thyroid nodules and malignancy [64, 65-66]. Although guidelines have been established, such as those of the Society of Radiologists in Ultrasound, the American Thyroid Association, and the European Thyroid Association [64, 67-68], they are commonly confusing and at times ignored in everyday practice, largely because of lack of familiarity with, and trust in, their validity. Common in the studies is a persistent limitation of specificity and sensitivity of specific ultrasound features in the prediction of malignancy. Some authors [69, 70] advocate a changed approach of recognition of specific patterns rather than individual ultrasound features in separation of nodules that require biopsy from those that do not. The purpose of our study was to evaluate the accuracy of such a morphologic feature-oriented approach to the identification of benign thyroid nodules.

Diagnosis of thyroid nodules

A thyroid nodule is a discrete lesion, sonographically distinct from the surrounding thyroid parenchyma [71]. Rather than a single disease, nodules are manifestations of a gamut of thyroid diseases [72]. Although some thyroid nodules may be discovered at physical examination, many are incidental findings of other imaging studies, such as CT and MRI of the neck or chest and carotid ultrasound imaging. FNA of thyroid nodules has replaced blind surgical excision as the procedure of choice in the

diagnosis of thyroid nodules. Use of FNA has led to a considerable decrease in the number of surgical excisions and to a twofold increase in the diagnosis of carcinoma [73, 74, 75]. The relative ease of FNA compared with surgery and the increased frequency and refinement of imaging studies has resulted in what some authors have referred to as an epidemic of thyroid nodules [76, 77].

In view of their ubiquity, it is not feasible to biopsy every thyroid nodule discovered with ultrasound. Reasons for limiting thyroid biopsy, which is relatively painless and safe, include the small percentage of malignant lesions, the small number of cases of thyroid cancer in which early diagnosis may actually have an influence, the economic and societal costs, the strain on radiology resources, and the patient uncertainty and anxiety incumbent on a potentially malignant diagnosis. Hence, reliable guidelines for nodules that may not require biopsy have become essential.

Not surprisingly in view of the experience of other authors [78], we concluded that no individual sonographic feature had both high sensitivity and high specificity in the detection of malignancy. Nonetheless, many of these previously described high-risk features, such as calcification, hypoechogenicity, poor definition, and hypervascularity, were found to be absent over and over again in nodules that did not require biopsy.

The persistent combination of some of these common individual ultrasound characteristics, or, more properly, their absence, led us to consider a more pattern-oriented approach, such as that advocated by Reading et al. [69] as an alternative to the analysis of individual features. Those authors described eight typical appearances of commonly encountered benign and malignant nodules, allowing them to separate more than one half of thyroid nodules into those that could be observed versus those requiring biopsy. According to their results, the following four classic patterns necessitate biopsy: 1, a hypoechoic nodule with microcalcifications; 2, coarse calcifications in a hypoechoic nodule; 3, well-marginated, ovoid, solid nodules with a thin hypoechoic halo; and 4, a solid mass with refractive shadowing from the edges, which is believed to occur as a result of fibrosis. The four classic patterns of nodules that did not require biopsy in that series were the following: 1, small (< 1 cm) colloid-filled cystic nodules; 2, a nodule with a honeycomb appearance consisting of internal cystic spaces with thin echogenic walls; 3, a large predominantly cystic nodule; and 4, diffuse multiple small hypoechoic nodules with intervening echogenic bands, which are indicative of Hashimoto's thyroiditis.

Like Reading et al. [69], we found that use of a pattern approach to thyroid nodules is highly sensitive and specific for the presence of benignity. Our patterns differed somewhat from those proposed previously, yet there are definite similarities. Analysis of our data revealed four patterns that were invariably benign at FNA biopsy. The most common overall pattern is a nodule with diffuse internal linear cysts, described as spongiform or

honeycomb, our type 1 pattern. In our cases, this finding was commonly described as a “puff pastry” pattern. This pattern was characteristic of colloid nodules or goiter. The only spongiform nodule not classically benign was a single nodule that also was intensely hypervascular. Our type 1 or spongiform nodule consequently is defined as avascular or, occasionally, isovascular in relation to the rest of the gland.

The second pattern (type 2) was a cystic nodule containing a central plug of avascular colloid, similar to the previously described small or large cyst patterns [69]. In our initial analysis of individual features, size of cyst was deemed insignificant. Important, however, was the characterization of the plug as avascular and puff pastry. All of these nodules were also colloid nodules. If the cystic portion of the lesion is subtracted visually, a type 1 spongiform nodule remains. The third pattern (type 3), or giraffe pattern, was characterized by globular areas of hyperechogenicity surrounded by linear thin areas of hypoechogenicity, similar to the two-tone blocklike coloring of a giraffe. This pattern was quite characteristic of Hashimoto’s thyroiditis. A variation of this pattern is our type 4 “white knight,” or hyperechoic, nodule, which was found commonly to be a regenerative nodule of Hashimoto’s thyroiditis.

Analysis of these patterns revealed more variability in final cytologic findings. Such nodules included both insignificant and significant lesions with such variability that prediction before biopsy was not reliable. These nodules had the four biopsy-recommendation patterns described earlier, such as isoechoic nodule with a surrounding halo or refractive edges, which came to be simplified as isoechoic nodules with or without a halo (types 7 and 8). A hypoechoic nodule with or without central microcalcification or with central macrocalcification in other series [79, 80, 81], for which biopsy was recommended, was the most worrisome pattern (type 6) in our study.

We identified other common patterns, including the type 5 “red light” pattern, or an intensely hypervascular lesion that on Doppler images glowed like a red stoplight. This pattern was commonly seen in lesions with abundant cellularity, including, commonly, follicular neoplasms and, less commonly, hyperplastic nodules and carcinoma. Other nodule types included type 9 ring-of-fire nodules with intense peripheral vascularity and nodules described as other (type 10), which did not fit any of the classic patterns. Calcification, although commonly seen in nodules requiring biopsy, was never seen as an isolated finding. The likelihood of benignity of these nodules (type 5-10) ranged from 60% (type 9, ring of fire) to 91% (type 10, other). Because of this lack of predictability, we believed that these nodules should be considered for FNA biopsy. A prominent application of US is detection of thyroid nodules and the differential diagnosis between thyroid carcinoma, especially papillary carcinoma, and a benign nodule [2–6]. To date, several US features (e.g., microcalcifications, hypo echogenicity, irregular margins, halo signs) have been identified as indicating papillary carcinoma. In Japan, a multicenter study showed that a jagged border, irregular

shape, and hypoechoic internal echo level are important characteristics for diagnosing papillary carcinoma [7].

To diagnose thyroid nodules accurately and immediately during mass US screening, a report along with scoring or categorization using a classification system is rational. Recently, classification systems for the diagnosis of thyroid nodules have been proposed.

Tae et al. [8] classified thyroid nodules into three categories based on their having one or more of four features: nodules with microcalcifications, an irregular or microlobulated margin, marked hypoechogenicity, and a shape that is taller than it is wide are classified as category 3 (malignant); nodules that show an absence of all of these features are classified as category 2 (benign); and anechogenic cystic nodules are classified as category 1 (benign). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 87%, 87%, 48%, and 98%, respectively, by comparing their findings with cytologic results.

In 2009, Horvath et al. [9] proposed the thyroid imaging reporting and data system (TIRADS). They established six categories (TIRADS 1 to TIRADS 6) based on US patterns and estimated the incidence of malignancy for each TIRADS class: 0% for TIRADS 1 and 2; 5% for TIRADS 3; 5–10% for TIRADS 4A; 10–80% for TIRADS 4B; 80% for TIRADS 5; and 100% for TIRADS 6. They diagnosed nodules with TIRADS 4 or greater as suspected of malignancy; they compared their classification results and FNAB findings and showed that the sensitivity, specificity, PPV, and NPV were 88, 49, 49, and 88%, respectively. In both studies, follicular lesions according to FNAB findings were classified as suspicious of malignancy.

We routinely evaluate nodules according to this system to diagnose the lesions as benign or malignant [10, 11]. The classification consists of five grades from US classes (USCs) 1 to 5 as summarized in Table 1.

Typical US profiles of each class are as follows: cyst for USC1; adenomatous nodule or, if multiple, multinodular goiter for USC2; follicular neoplasm (including minimally invasive follicular carcinoma) for USC3; thyroid carcinoma (papillary carcinoma, widely invasive follicular carcinoma, medullary carcinoma, and anaplastic carcinoma) for USCs 4 and 5. Furthermore, we set intermediate classes from USC 2 to USC 5—designated USCs 2.5, 3.5, and 4.5. Nodules showing cystic change but having a partially irregular shape and/or showing strong echoes and solid nodules with an irregular shape are classified as USC 2.5 and 3.5, respectively. A solid, irregularly shaped nodule showing minor extrathyroid extension is classified as USC 4.5. Nodules classified as USC 2.5 or lower are evaluated as benign nodules; those with USC 3 are evaluated as follicular neoplasms, including minimally invasive follicular carcinoma; and those considered USC 3.5 or greater are diagnosed as, or suspected of, thyroid carcinoma.

Table 1: US classification for thyroid nodules at Kuma Hospital

USC	Diagnosis
Round or oval anechoic lesion	Cyst
Regularly shaped nodule with cystic change (echo level of a solid lesion is similar to that of normal thyroid)	Adenomatous nodule Multinodular goiter
Solid, regularly shaped nodule (internal echo is homogeneous or may have strong echoes internally or at the capsule)	Follicular adenoma Minimally invasive follicular carcinoma
Solid, irregularly shaped nodule (internal echo is usually low and may have fine strong echoes internally)	Thyroid carcinoma
Solid, irregularly shaped nodule with extrathyroid extension	Thyroid carcinoma

When nodules are diagnosed as carcinoma on US and FNAB, the evaluation of their location is important. When carcinoma is located in the dorsal surface of the thyroid, it may extend to the adjacent organs—recurrent laryngeal nerve, trachea, esophagus—and require resection of these organs to achieve curative surgery. US can provide information to surgeons indicating whether a carcinoma carries a risk of extending to other organs. Tomoda et al. [12] investigated the diagnostic accuracy of US regarding tracheal invasion by papillary carcinoma and showed that the sensitivity, specificity, PPV, and NPV were 91, 93, 25, and 99%, respectively. However, such findings cannot be evaluated for tumors having severe calcifications, large size, or extension inferior to the clavicle. In their series, 32 of 509 patients (6%) could not be evaluated. Other imaging studies such as CT and MRI can be useful for evaluating such tumors.

One important issue that physicians must consider is the management of small carcinomas detectable on US, most of which are papillary carcinoma measuring < 1 cm (papillary microcarcinoma, or PMC). The incidence of PMC classified into USC 3.5 or greater does not differ from that of larger carcinomas [11], indicating that it is not difficult to detect and diagnose PMC on US and US-guided FNAB. However, we must note that there has been a high incidence of microcarcinomas detected in some autopsy studies [13–15], and thyroid carcinomas (mostly < 1.5 cm) have been found in as many as 3.5% of otherwise healthy women over 30 years of age during US mass screening and FNAB [16]. These findings definitely indicate that most low-risk PMCs lacking clinically apparent nodal and/or distant metastases and massive extension to adjacent organs are not harmful to patients throughout their lives. Thus, we must carefully consider whether “early detection” of such small carcinomas and performing thyroidectomy routinely for them are truly beneficial for patients. In our institution since 1993, we have used observation alone for low-risk PMCs without immediate surgical treatment, with the result that only 6.7% of patients showed tumor enlargement after a 5-year follow up, and none of the patients showed distant metastasis or died of carcinoma during the observation [17–19]. It is suggested that routine surgical treatment for PMC forces unnecessary therapy on most PMC patients. Indeed, this is a pitfall of the

technical development of imaging studies, and we propose observation without immediate surgical treatment for low-risk PMC as an alternative to initial treatment.

It is difficult to determine whether a nodule that has US features indicating a follicular tumor (USC 3 in our classification system) is follicular carcinoma or benign adenoma, which is a limitation of routine US [20, 21]. To date, several clinicopathologic features—tumor size, patient’s sex, patient’s age, indeterminate cytology, serum thyroglobulin level—have been reported as risk factors for follicular carcinoma [22, 23]. However, if more accurate evaluation on imaging studies becomes possible, the indications for surgery for such nodules could be narrowed.

Fukunari et al. [24] proposed a diagnostic grading system based on the findings of B-mode US and color Doppler findings, including tumor vascularity and blood flow analysis objectively indicated as the pulsatility index (PI). They reported favorable results of their examination, with the sensitivity 89% and the specificity 74%. Furthermore, real-time tissue elastography (RTE) may provide novel information for diagnosis of follicular carcinoma. Fukunari [25] reported that the sensitivity and specificity of RTE for follicular carcinoma were 83% and 98%, respectively. Also, Rogo et al. [26] demonstrated that RTE is a useful tool for diagnosing thyroid carcinoma, especially nodules with indeterminate cytology. Further studies for these new techniques by a number of institutions are desired to improve the diagnostic accuracy of follicular carcinoma on US.

Diagnosis of lymph node metastasis

Three prominent compartments of regional lymph nodes are affected by thyroid carcinoma: the central, lateral and mediastinal compartments. US is the most useful tool for evaluating lymph node metastasis except for that in the mediastinal compartment [27, 28]. Preoperative evaluation of lymph node metastasis of thyroid carcinoma is important because it determines the extent of lymph node dissection and predicts patient outcomes. We previously showed that metastasis in the lateral compartment detectable on US (N1b) is an independent prognostic factor for

disease-free survival (DFS) and cancer-specific survival (CSS) on multivariate analysis [29, 30]. Furthermore, a study of a subset of N1b patients showed that those having five or more clinically apparent metastases, a metastasis > 3 cm, or extranodal tumor extension showed a more adverse prognosis than those having none of these features [31]. Of these three features, the former two can be preoperatively evaluated on US. Therefore, evaluation of metastasis, especially in the lateral compartment, on US is essential to determine if the surgeon should perform lateral compartment dissection (modified radical neck dissection, or MND) and to predict the clinical outcomes of patients.

To date, several US features—large size, round shape, hypoechoic structure, loss of hilar architecture, hyperechoic punctuations, microcalcifications, cystic appearance—have been proposed by various institutions [32–36]. In 1995, Antonelli et al. [37] proposed US criteria for lymph node metastasis: size larger than 1 cm; clear hypoechoic pattern or dyshomogeneous pattern, with alternating hypoechoic and hyperechoic areas; irregular cystic appearance; the presence of internal calcification; and rounded or bulging shape with an increased anteroposterior diameter. These criteria have been widely accepted, although our institution has not adopted lymph node size as a criterion.

The diagnostic accuracy of an US diagnosis of node metastasis is, however, not very high because the high specificity is offset by low sensitivity. Leboulleux et al. [38] compared various features of lymph nodes and pathologic diagnoses for 56 nodes in 19 patients and demonstrated that cystic appearance, hyperechogenic punctuations, and peripheral vascularization are useful criteria for node metastasis because their specificities are high, at 100, 100, and 82%, respectively. However, the sensitivities of the former two are low, at 11 and 46%, respectively. The sensitivity of peripheral vascularization was high at 86%, although the number of patients examined was small.

We also investigated the diagnostic accuracy of US for lateral node metastasis using a series of 3,974 patients who underwent therapeutic or prophylactic MND [31]. Although the specificity and PPV were high, at 97 and 95%, respectively, the sensitivity and NPV were low, at 30 and 43%, respectively. We have adopted FNAB for nodes suspected of metastasis along with the measurement of thyroglobulin levels in the washout of needles used for FNAB to confirm the diagnosis of metastasis [39]. It is useful to increase the specificity and PPV, but it does not improve sensitivity or NPV.

Kim et al. [40] showed that for preoperative detection of lateral node metastasis the combination of US and CT is more accurate than US alone, but the tendency toward high specificity and low sensitivity was not changed. As for metastasis to the central node, sensitivity and NPV were even worse, at only 12 and 37%, respectively [31]. This is probably because detection of lymph nodes is made difficult by the air-filled trachea and the thyroid itself.

The above findings indicate that US rather frequently overlooks lymph node metastasis in the central and lateral compartments and that there are many false-negative results in cases diagnosed as negative for node metastasis on US. These pitfalls distress surgeons trying to decide on the extent of lymph node dissection. Compartments showing clinically apparent metastasis definitely should be therapeutically dissected, but the indication for prophylactic dissection remains controversial. Dissection of the central compartment does not require wound extension and can be performed within the same surgical field as thyroidectomy. In addition, the diagnostic accuracy of central compartment metastasis on US is low and reoperation for recurrence to this compartment often causes recurrent laryngeal nerve injury and permanent hypoparathyroidism [41, 42].

In contrast, MND requires wound extension, is time-consuming and technically difficult, and increases patients' complaints, although some of these concerns can be compensated by the skill of the surgeon. Prophylactic MND is recommended for patients exhibiting a high incidence of recurrence to the nodes. The indication for prophylactic MND is affected by the incidence of nodal recurrence rates that patients and physicians can accept. Our department recommends prophylactic MND for patients having two or more of the following characteristics—male sex, > 55 years of age, tumor > 3 cm, and massive extra thyroid extension—because the 10-year lymph node DFS of those patients was < 90%; that is, lymph node recurrence rates were more than 10%, even though the patients underwent prophylactic MND [29]. Sugitani et al. [43] proposed that prophylactic MND is indicated for patients with a tumor > 4 cm or metastasis to distant organs at surgery.

Diagnosis of malignant lymphoma of the thyroid

Malignant lymphoma of the thyroid accounts for 2–5% of all thyroid malignancies and usually arises from chronic thyroiditis [44–47]. This disease can usually be diagnosed on FNAB; to confirm the histologic type, surgical examination such as open biopsy or thyroidectomy is useful [48].

Furthermore, investigations for rearrangement of the IgH gene, CD45 gating, and chromosomal abnormality are helpful for diagnosis [49]. The prognosis of thyroid lymphoma is generally favorable if treated competently [50–53], but it can suddenly enlarge, causing life-threatening asphyxia. Therefore, early detection and diagnosis are mandatory to initiate appropriate therapy during an early phase of the disease.

For early detection of thyroid lymphoma, a differential diagnosis between thyroid lymphoma and severe chronic thyroiditis is essential; and US is an extremely useful tool for this purpose. There are three US-detected patterns of thyroid lymphoma: nodular, diffuse and mixed [54]. The nodular type displays hypoechoic, homogeneous internal echoes with a well-defined border showing a broccoli-like or coastline-like growth pattern. Posterior echoes are broadly

Table 2: Ultrasonographic classification of thyroid lymphoma

Ultrasonographic classification of thyroid lymphoma			
Type	Internal echoes	Border	Posterior echoes
Nodular	Hypoechoic and homogeneous nodular lesions	Broccoli-like Coastline-like	Enhanced
Diffuse	Internal echoes	-	Enhanced
Mixed	Internal echoes	-	Enhanced

enhanced. The diffuse type also displays hypoechoic internal echoes, but the border between the lymphoma and nonlymphomatous tissue is not clear. Therefore, it is difficult to differentiate diffuse-type lymphoma and severe chronic thyroiditis, although enhanced posterior echoes are useful for diagnosing lymphoma of this type. Patchy hypoechoic lesions can be observed in the thyroid in mixed-type lymphoma. The US profile of mixed-type lymphoma often resembles multinodular goiter, but each lymphoma lesion shows enhanced posterior echoes. The US classification of these three types is summarized in Table 2. Enhanced posterior echoes are typical findings of thyroid lymphoma regardless of type, and lesions having this feature should be suspected of being a thyroid lymphoma, in which case further analyses such as FNAB are recommended.

In Kuma hospital, among 170 patients suspected of having a thyroid lymphoma based on US findings between 2000 and 2004, a total of 74 (43.5%) were diagnosed as having or suspected of having lymphoma on FNAB [53]. In all, 69 of these patients underwent incisional biopsy or thyroidectomy, and 67 were diagnosed as having lymphoma on the pathology examination. Of 96 patients who were not cytologically diagnosed as having or suspected of having lymphoma, 20 underwent a surgical procedure because lymphoma was suspected by the attending physicians. Of these 20 patients, 12 were diagnosed pathologically as having lymphoma. In total, 79 of 170 patients (46.5%) were confirmed as having lymphoma on the pathology examination.

The number of patients diagnosed as having lymphoma is increasing because only 116 patients were treated with lymphoma between 1963 and 1990 in our institution [48]. This is definitely because the resolution power of US has enabled the detection of lymphoma in an early phase. In a series between 1963 and 1990, a total of 78% of patients complained of rapid enlargement of a goiter, but only 22% of patients in a series between 2000 and 2004 showed rapid goiter enlargement [54]. US-guided FNAB is the next step for diagnosing thyroid lymphoma. In our department, the PPV for FNAB is 97.1%, indicating that cytologic examination after candidates for FNAB are selected based on US findings contributed markedly to the diagnosis of lymphoma. However, at least 12.5% of patients (12/96 patients) were misdiagnosed on FNAB, indicating that all patients suspected of lymphoma on US should be followed carefully, even though the FNAB diagnosis is negative. We encountered a patient who

exhibited a serial change from chronic thyroiditis to lymphoma over an interval of at least 7 years [55].

Surgical examination is also important for establishing the final diagnosis and confirming the histologic type to facilitate any decisions on therapy, such as irradiation only or irradiation with systemic chemotherapy. In the past, incisional or core needle biopsy was performed in most patients, but at present the incidence of thyroidectomy (e.g., lobectomy, total thyroidectomy) has increased significantly. Indeed, in our series between 2000 and 2004, a total of 65% of patients underwent thyroidectomy [54]. As indicated above, the incidence of early detection of lymphoma is increasing, and most patients show a low level of malignancy. For such cases, biopsy from the surface of the thyroid only causes misdiagnosis, and thyroidectomy should be actively performed to achieve an accurate diagnosis, which might also have therapeutic value.

Differential diagnosis between painless thyroiditis and Graves' disease

Thyrotoxicosis in patients without hyperfunctioning nodules is due to destruction-induced thyrotoxicosis and Graves' disease. Destruction-induced thyrotoxicosis may be observed in patients with painless thyroiditis, postpartum thyroiditis, and/or subacute thyroiditis [56]. It is often difficult to differentiate between painless thyroiditis and Graves' disease. There are several strategies to differentiate these diseases, among which are radioactive iodine uptake (RAIU) and the detection of anti-thyroid-stimulating hormone (TSH) receptor antibodies (TSH binding inhibitory immunoglobulin, or TBII). During the early postpartum period, destruction-induced thyrotoxicosis is more likely to occur than Graves' disease, although Amino et al. [57] showed that Graves' thyrotoxicosis may also occur 3–6 months postpartum. RAIU cannot be performed when patients are lactating; and not all clinics are equipped for this examination. TBII is, indeed, a useful marker of Graves' thyrotoxicosis because it is positive in 99–100% of patients [58, 59]. However, TBII was also positive in 6–15% of patients with painless thyroiditis, indicating that TBII is not always reliable for differentiating these two diseases [60–62].

Recently, measurement of thyroid blood flow (TBF) was reported to be another useful strategy for differentiating painless thyroiditis from Graves' disease [63]. The quantification of TBF can be expressed in a percentage

as an advanced dynamic flow/region of interest (ADF/ROI) ratio by special software. ADF is a recently developed high-resolution power Doppler mode used as a quantitative method for calculating TBF; it can present clearer information of minute blood flow than traditional power Doppler mode. TBF was significantly higher ($p < 0.0001$) in Graves' disease than in painless thyroiditis, subacute thyroiditis, or normal controls. The TBF of patients with Graves' disease was always $> 4\%$, and all other patients had TBF $< 4\%$, indicating that 4% is the cutoff for distinguishing destruction-induced thyrotoxicosis and Graves' disease. The TBF of patients with painless thyroiditis and those with Graves' disease were significantly correlated with the RAIU [63]. This examination is a candidate for diagnosing thyrotoxicosis as an alternative to RAIU in the future.

Conclusions

Recent technical developments in US have facilitated the differentiation of malignant and benign nodules and metastatic and reactive lymph nodes; of whether a nodule is malignant or benign; whether lymph node is metastatic or reactive; whether a hypoechoic lesion is lymphoma or chronic thyroiditis; and whether thyrotoxicosis is due to painless thyroiditis or Graves' diseases. To establish an accurate and immediate diagnosis of thyroid nodules, the development of a classification system is rational. We established our own system in 1995 and showed favorable results. This system is simple and easy to use, indicating that it is appropriate for performing US in many patients over a short time in a screening process.

At present, thyroid nodules measuring 3 mm can be detected on US and diagnosed as malignant or benign on US-guided FNAB. However, due to the excessive resolving power of US, small and harmless thyroid carcinomas have frequently been found and a number of patients would undergo unnecessary surgical treatment if physicians recommended surgery for all such lesions. In our opinion, observation without immediate surgical treatment for low risk PMC can be a potent alternative initial treatment.

The diagnostic accuracy of US, especially the sensitivity, for lymph node metastasis is low, indicating that many metastatic nodes may remain undissected if the compartment is not dissected prophylactically. However, the incidence of such latent metastasis becoming clinically apparent is not high. In our opinion, prophylactic central node dissection should be performed to avoid severe complications at the time of possible reoperation in the future. Prophylactic MND is recommended for selected patients who have clinicopathologic features that predict a high incidence of lymph node recurrence. The indication for prophylactic MND is affected by the incidence of nodal recurrence rates that patients and physicians can accept.

Ultrasonography facilitates the selection of patients suspected of thyroid lymphoma. Early detection of thyroid lymphoma is now possible, which contributes to achiev-

ing a favorable prognosis for patients. Among patients who are suspected of having a lymphoma based on US findings, those diagnosed as having lymphoma on FNAB should immediately undergo surgical examination to confirm the histology. Thereafter, they should undergo appropriate therapy based on the pathologic findings. However, patients diagnosed as negative on FNAB should also be carefully followed because at least 13% of these patients were confirmed to have lymphoma in our series.

The biopsy of a large number of thyroid nodules can be avoided when a pattern approach to nodule characterization is used. Specific morphologic patterns are highly predictive of benignity. Specifically, a nodule that has a uniform nonhypervascular spongiform appearance, is a cystic lesion with a colloid clot, has a giraffelike pattern, or is diffusely hyperechoic can be observed rather than biopsied. If, conversely, a nodule does not correspond to one of these four patterns, according to our data biopsy should be performed regardless of the individual features or pattern of the nodule.

Routine analysis of TBF for patients with untreated thyrotoxicosis is helpful for differentially diagnosing patients with destruction-induced thyrotoxicosis from those with Graves' disease.

The remaining issue to be solved is the differential diagnosis between follicular carcinoma and benign adenoma. Trials using novel techniques are progressing at a number of institutions, and publication of their findings is expected.

References

1. Yokozawa T, Miyauchi A, Kuma K et al (1995). Accurate and simple method of diagnosing thyroid nodules the modified technique of ultrasound-guided fine needle aspiration biopsy. *Thyroid* 5:141–145
2. Hegedus L (2001) Thyroid ultrasound. *Endocrinol Metab Clin North Am* 30:339
3. Koike E, Noguchi S, Yamashita H et al (2001). Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. *Arch Surg* 136:334–337
4. Rojeski MT, Gharib H (1985) Nodular thyroid disease: evaluation and management. *N Engl J Med* 313:428–436
5. Natori H (1999). Diagnostic criteria for thyroid nodules. *J Med Ultrasonics* 26:149–150
6. Papini E, Guglielmi R, Bianchini A et al (2002). Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. *J Clin Endocrinol Metab* 87:654–657
7. Shimura H, Haraguchi K, Hiejima Y et al (2005). Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: a multicenter study. *Thyroid* 15:251–258
8. Tae HJ, Im DJ, Baek KH et al (2007). Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. *Thyroid* 17:461–465

9. Horvath E, Majlis S, Rossi R et al (2009). An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. *J Clin Endocrinol Metab* 90:1748–1751
10. Yokozawa T, Fukata S, Kuma K et al (1996). Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy. *World J Surg* 20:848–853
11. Ito Y, Amino N, Ota H et al (2007). Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. *Thyroid* 17:1269–1276
12. Tomoda C, Uruno T, Takamura Y et al (2005). Ultrasonography as a method of screening for tracheal invasion by papillary thyroid cancer. *Surg Today* 35:819–822
13. Harach HR, Franssila KO, Wasenius VM (1985). Occult papillary carcinoma of the thyroid: a “normal” finding in Finland—a systematic autopsy study. *Cancer* 56:531–538
14. Fukunaga FH, Yatani R (1975). Geographic pathology of occult thyroid carcinomas. *Cancer* 36:1095–1099
15. Thorvaldsson SE, Tulinius H, Bjornsson J et al (1992). Latent thyroid carcinoma in Iceland at autopsy. *Pathol Res Pract* 188:747–750
16. Takebe K, Date M, Yamamoto Y et al (1994). Mass screening for thyroid cancer with ultrasonography. *Karkinos* 7:309–317 (in Japanese)
17. Ito Y, Uruno R, Nakano K et al (2003). An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* 13:381–388
18. Ito Y, Tomoda C, Uruno T et al (2004). Papillary microcarcinoma of the thyroid: how should it be treated? *World J Surg* 28:1115–1121
19. Ito Y, Miyauchi A (2007). A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. *Nat Clin Pract Endocrinol Metab* 3:240–248
20. Kobayashi K, Fukata S, Miyauchi A (2005). Diagnosis of follicular carcinoma of the thyroid: role of sonography in preoperative diagnosis of follicular carcinoma. *J Med Ultrasonics* 32:153–158
21. Hageg P, Straus S, Weiss M (1998). Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. *Thyroid* 11:989–995
22. Tuttle RM, Lemar H, Burch HB (1998). Clinical features associated with an increased risk of malignancy in patients with follicular neoplasia by fine-needle aspiration. *Thyroid* 8:377–383
23. Schlinkert RT, Van Heerden JA, Goeliner JR et al (1997). Factors that predict malignant thyroid lesions when fine-needle aspiration is suspicious for follicular neoplasms. *Mayo Clin Proc* 72:913–916
24. Fukunari N, Nagahama M, Sugino K et al (2004). Clinical evaluation of color Doppler imaging for the differentiated diagnosis of thyroid follicular lesion. *World J Surg* 28:1261–1265
25. Fukunari N (2007). Ultrasonography of thyroid cancer. *Nippon Rinsho* 65:1997–2002 (in Japanese)
26. Rogo T, Santini F, Scutari M et al (2007). Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. *J Clin Endocrinol Metab* 92:2917–2922
27. Ito Y, Miyauchi A (2007). Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits and risks. *World J Surg* 31:905–915
28. Ito Y, Miyauchi A (2008). Lateral lymph node dissection guided by preoperative and intra-operative findings in differentiated thyroid carcinoma. *World J Surg* 32:729–739
29. Ito Y, Higashiyama T, Takamura Y et al (2007). Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. *World J Surg* 31:2085–2091
30. Ito Y, Miyauchi A (2009). Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. *Endocr J* 56:177–192
31. Ito Y, Fukushima M, Tomoda C et al (2009). Prognosis of patients with papillary carcinoma having clinically apparent metastasis to the lateral compartment. *Endocr J* 56:759–766
32. Van den Brekel MW, Castelijns JA, Snow GB (1998). The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? *Am J Neuroradiol* 19:695–700
33. Dragoni F, Cartoni C, Pescarmona E et al (1999). The role of high resolution pulsed and color Doppler ultrasound in the differential diagnosis of benign and malignant lymphadenopathy: results of multivariate analysis. *Cancer* 85:2485–2490
34. Wang Q, Takashima S, Takayama F et al (2001). Detection of occult metastatic lymph nodes in the neck with gray-scale and power Doppler US. *Acta Radiol* 42:312–319
35. Kessler A, Rapaport Y, Blank A et al (2003). Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma. *J Clin Ultrasound* 31:21–25
36. Kuna SK, Bracic I, Tesic V et al (2006). Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. *J Ultrasound Med* 25:1531–1537
37. Antonelli A, Miccoli P, Ferdeghini M et al (1995). Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. *Thyroid* 5:25–28
38. Leboulleux S, Girard E, Rose M et al (2007). Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab* 92:3590–3594
39. Uruno T, Miyauchi A, Shimizu K et al (2005). Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. *World J Surg* 29:483–485
40. Kim E, Park JS, Son KR et al (2009). Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. *Thyroid* 18:411–418
41. Kim MK, Mandel SH, Baloch Z et al (2004). Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. *Arch Otolaryngol Head Neck Surg* 130:1214–1216

42. Martensson H, Terins J (1985). Recurrent laryngeal nerve palsy in thyroid gland surgery related to operations and nerve at risk. *Arch Surg* 120:475–477
43. Sugitani I, Fujimoto Y, Yamada K et al (2008). Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. *World J Surg* 32:2494–2502
44. Aozasa K, Inoue A, Tajima K et al (1986). Malignant lymphoma of the thyroid gland: analysis of 79 patients with emphasis on histologic prognostic factors. *Cancer* 58:100–104
45. Staunton HD, Greening WP (1973). Clinical diagnosis of thyroid cancers. *BMJ* 4:532–535
46. Kato I, Tajima K, Aozasa K et al (1985). Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. *Jpn J Cancer Res* 40:459–468
47. Aozasa K (1990). Hashimoto's thyroiditis as a risk factor of thyroid lymphoma. *Acta Pathol Jpn* 40:459–468
48. Matsuzuka F, Miyauchi A, Katayama S et al (1993). Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. *Thyroid* 3:93–99
49. Matsuzuka F, Fukata S, Kuma K et al (1998). Gene rearrangement of immunoglobulin as a marker of thyroid lymphoma. *World J Surg* 22:558–561
50. Derringer GA, Thompson LDR, Frommelt A et al (2000). Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. *Am J Surg Pathol* 24:623–639
51. Tupchong L, Phil D, Hughes F et al (1986). Primary lymphoma of the thyroid gland: clinical features, prognostic factors, and results of treatment. *Int J Radiat Oncol Biol Phys* 12:1813–1821
52. Chak LY, Hoppe RT, Burke JS et al (1981). Non-Hodgkin's lymphoma presenting as thyroid enlargement. *Cancer* 48:2712–2716
53. Sirota DS, Segal RL (1979). Primary lymphoma of the thyroid gland. *JAMA* 242:1743–1746
54. Ota H, Ito Y, Matsuzuka F et al (2006). Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid. *Thyroid* 16:983–987
55. Matsuzuka F, Amino N, Kuma K et al (2005). Serial changes in thyroid ultrasonogram in a patient with Hashimoto's thyroiditis who developed malignant lymphoma. *Thyroid* 15:742–743
56. Amino N, Yabu Y, Miki T et al (1981). Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis. *J Clin Endocrinol Metab* 53:113–116
57. Amino N, Tada H, Hidaka Y (1996). The spectrum of postpartum thyroid dysfunction: diagnosis, management, and long-term prognosis. *Endocr Pract* 2:406–410
58. Costagliola S, Morgenthaler NG, Hoermann R et al (1999). Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. *J Clin Endocrinol Metab* 84:90–97
59. Schott M, Feldkamp J, Bathan C et al (2000). Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. *Horm Metab Res* 32:429–435
60. Morita T, Tamai H, Oshima A et al (1990). The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis. *J Clin Endocrinol Metab* 71:1051–1055
61. Kamijo K (2003). TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor. *Endocr J* 50:113–116
62. Iitaka M, Morgenthaler NG, Momotani N et al (2004). Stimulation of thyroid-stimulating hormone (TSH) receptor antibody production following painless thyroiditis. *Clin Endocrinol (Oxf)* 60:49–53
63. Ota H, Amino N, Morita S et al (2007). Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. *Clin Endocrinol (Oxf)* 67:41–45
64. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. *Radiology* 2005; 237:794-800
65. Jun P, Chow LC, Jeffrey RB. The sonographic features of papillary thyroid carcinomas: pictorial essay. *Ultrasound Q* 2005; 21:39-45
66. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. *J Clin Endocrinol Metab* 2006; 91:3411-3417
67. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006; 16:109-142
68. Van De Velde CJ, Hamming JF, Goslings BM, et al. Report of the consensus development conference on the management of differentiated thyroid cancer in The Netherlands. *Eur J Cancer Clin Oncol* 1988; 24:287-292
69. Reading CC, Charboneau JW, Hay ID, Sebo TJ. Sonography of thyroid nodules: a "classic pattern" diagnostic approach. *Ultrasound Q* 2005; 21:157-165
70. Hegedus L. Thyroid ultrasound. *Endocrinol Metab Clin North Am* 2001; 30:339-360
71. Vandermeer FQ, Wong-You-Cheong J. Thyroid nodules: when to biopsy. *Appl Radiol* 2007; 36:8-19
72. Pacini F, Burroni L, Ciulli C, Di Cairano G, Guarino E. Management of thyroid nodules: a clinicopathological, evidence-based approach. *Eur J Nucl Med Mol Imaging* 2004; 31:1443-1449
73. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005; 55:10-30 [Erratum in *CA Cancer J Clin* 2005; 55:259]
74. Harnsberger H. Diagnostic imaging: head and neck. Salt Lake City, UT: Amirsys, 2004:24-40
75. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. *Endocr Pract* 2003; 9:128-136
76. Brander AE, Viikinkoski VP, Nickels JI, Kivisaari LM. Importance of thyroid abnormalities detected at US screening: a 5-year follow-up. *Radiology* 2000; 215:801-806

77. Ross DS. Nonpalpable thyroid nodules: managing an epidemic. *J Clin Endocrinol Metab* 2002; 87:1938-1940
78. Sahin M, Sengul A, Berki Z, Tutuncu NB, Guvener ND. Ultrasound-guided fine-needle aspiration biopsy and ultrasonographic features of infracentimetric nodules in patients with nodular goiter: correlation with pathological findings. *Endocr Pathol* 2006; 17:67-74
79. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US features of thyroid malignancy: pearls and pitfalls. *RadioGraphics* 2007; 27:847-860
80. Takashima S, Fukuda H, Nomura N, Kishimoto H, Kim T, Kobayashi T. Thyroid nodules: reevaluation with ultrasound. *J Clin Ultrasound* 1995; 23:179-184
81. Iannuccilli JD, Cronan JJ, Monchik JM. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. *J Ultrasound Med* 2004; 23:1455-1464